UM729 is a pyrimido-[4,5-b]-indole derivative which enhances the self-renewal of human hematopoietic stem cells in vitro. UM729 does not inhibit the aryl hydrocarbon receptor (AHR) pathway, but has been shown to collaborate with AHR antagonists in preventing differentiation of acute myeloid leukemia (AML) cells in culture.
MAINTENANCE AND SELF-RENEWAL
· Enhances human hematopoietic stem cell self-renewal in vitro (Fares et al.).
· Collaborates with StemRegenin 1 (SR1) in preventing differentiation of AML cells in culture (Pabst et al.).
For clinical use of UM729, please contact ExCellThera.
Cancer Cells and Cell Lines, Hematopoietic Stem and Progenitor Cells, Leukemia/Lymphoma Cells
Hematopoietic Stem and Progenitor Cells - Products for Your Research
UM171 & UM729: Novel Small Molecules for the Ex Vivo Expansion of Human Hematopoietic Stem Cells
Culturing Leukemic Stem & Progenitor Cells with StemSpan™ Medium
New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells
Troubleshooting In Vitro Expansion of Leukemic Cells
This product is designed for use in the following research area(s) as part
of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we
offer to support each research area.
The small number of hematopoietic stem and progenitor cells in cord blood units limits their widespread use in human transplant protocols. We identified a family of chemically related small molecules that stimulates the expansion ex vivo of human cord blood cells capable of reconstituting human hematopoiesis for at least 6 months in immunocompromised mice. The potent activity of these newly identified compounds, UM171 being the prototype, is independent of suppression of the aryl hydrocarbon receptor, which targets cells with more-limited regenerative potential. The properties of UM171 make it a potential candidate for hematopoietic stem cell transplantation and gene therapy.
Nature methods 2014 APR
Identification of small molecules that support human leukemia stem cell activity ex vivo.
Pabst C et al.
Leukemic stem cells (LSCs) are considered a major cause of relapse in acute myeloid leukemia (AML). Defining pathways that control LSC self-renewal is crucial for a better understanding of underlying mechanisms and for the development of targeted therapies. However, currently available culture conditions do not prevent spontaneous differentiation of LSCs, which greatly limits the feasibility of cell-based assays. To overcome these constraints we conducted a high-throughput chemical screen and identified small molecules that inhibit differentiation and support LSC activity in vitro. Similar to reports with cord blood stem cells, several of these compounds suppressed the aryl-hydrocarbon receptor (AhR) pathway, which we show to be inactive in vivo and rapidly activated ex vivo in AML cells. We also identified a compound, UM729, that collaborates with AhR suppressors in preventing AML cell differentiation. Together, these findings provide newly defined culture conditions for improved ex vivo culture of primary human AML cells.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Contact STEMCELL Technologies
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
your email preferences at any time.